HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks.
HER2
antibody–drug conjugates
breast cancer
monoclonal antibodies
tyrosine kinase inhibitors
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
11
2022
accepted:
20
01
2023
entrez:
27
2
2023
pubmed:
28
2
2023
medline:
28
2
2023
Statut:
epublish
Résumé
Around 20% of breast cancers are associated with amplification or overexpression of human epidermal growth factor receptor 2 (HER2). In this setting, anti-HER2-targeted agents are the cornerstone of cancer therapeutic strategies. This includes monoclonal antibodies, tyrosine kinase inhibitors (TKIs) and, recently, antibody-drug conjugates (ADCs). With the advent of these new alternatives, the decision-making process has become more complex, especially with regard to the treatment sequence possibilities. In spite of the fact that overall survival has significantly improved accordingly, resistance to treatment remains a challenge in HER2-positive breast cancer. The introduction of new agents has created awareness regarding new potential specific adverse events, and consequently, their increasing application pose major challenges in daily patient care. This review describes the therapeutic landscape for HER2-positive advanced breast cancer (ABC) and evaluates its benefits and risks in the clinical setting.
Identifiants
pubmed: 36844609
doi: 10.2147/OTT.S335934
pii: 335934
pmc: PMC9948634
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
115-132Informations de copyright
© 2023 Mandó et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
JAMA Oncol. 2018 Sep 1;4(9):1214-1220
pubmed: 29955792
J Clin Oncol. 2010 Mar 1;28(7):1124-30
pubmed: 20124187
Drug Deliv. 2022 Dec;29(1):1335-1344
pubmed: 35506447
Clin Cancer Res. 2009 Feb 15;15(4):1452-9
pubmed: 19228746
N Engl J Med. 2022 Mar 24;386(12):1143-1154
pubmed: 35320644
Invest Radiol. 2011 Nov;46(11):718-25
pubmed: 21788908
Lancet Oncol. 2013 Jan;14(1):64-71
pubmed: 23122784
N Engl J Med. 2012 Jan 12;366(2):109-19
pubmed: 22149875
Clin Cancer Res. 2011 Jul 15;17(14):4834-43
pubmed: 21768129
Eur J Cancer. 2019 Mar;109:92-102
pubmed: 30708264
Lancet Oncol. 2020 Oct;21(10):1283-1295
pubmed: 33002436
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Eur J Pharm Sci. 2017 Dec 15;110:51-61
pubmed: 28115222
Oncogene. 2009 Feb 12;28(6):803-14
pubmed: 19060928
Ann Oncol. 2020 Sep;31(9):1231-1239
pubmed: 32461105
Cancer Res. 2007 Sep 15;67(18):8882-90
pubmed: 17875730
Eur Heart J Cardiovasc Imaging. 2022 Sep 10;23(10):e333-e465
pubmed: 36017575
Clin Cancer Res. 2020 Nov 15;26(22):5820-5829
pubmed: 32938620
ESMO Open. 2022 Jun;7(3):100475
pubmed: 35490579
Clin Cancer Res. 2019 Apr 15;25(8):2433-2441
pubmed: 30593513
Lancet Oncol. 2017 Nov;18(11):1512-1522
pubmed: 29037983
Breast Cancer Res Treat. 2021 Feb;185(3):863-868
pubmed: 33400034
Lancet Oncol. 2020 Apr;21(4):519-530
pubmed: 32171426
J Clin Oncol. 2018 Oct 1;36(28):2826-2835
pubmed: 30106636
Crit Rev Oncol Hematol. 2022 Aug;176:103747
pubmed: 35717006
Cancer Sci. 2022 Sep;113(9):3169-3179
pubmed: 35754298
Drug Saf. 2008;31(6):459-67
pubmed: 18484781
J Clin Oncol. 2017 Sep 10;35(26):3030-3038
pubmed: 28437161
Ann Oncol. 2022 Mar;33(3):321-329
pubmed: 34954044
Lancet Oncol. 2014 Jun;15(7):689-99
pubmed: 24793816
ESMO Open. 2021 Apr;6(2):100099
pubmed: 33819752
Ann Oncol. 2013 Jun;24(6):1526-33
pubmed: 23463626
Ann Pharmacother. 2016 Sep;50(9):712-7
pubmed: 27307412
Lancet Oncol. 2019 Aug;20(8):1124-1135
pubmed: 31257177
ESMO Open. 2021 Oct;6(5):100256
pubmed: 34482180
Cold Spring Harb Perspect Med. 2020 Jun 1;10(6):
pubmed: 31615863
J Natl Compr Canc Netw. 2022 Jun;20(6):691-722
pubmed: 35714673
Lancet Oncol. 2021 Mar;22(3):351-360
pubmed: 33581774
Mol Cancer Ther. 2020 Apr;19(4):976-987
pubmed: 32241871
Breast Cancer Res Treat. 2012 Sep;135(2):347-54
pubmed: 22782294
Cancer Cell. 2004 Apr;5(4):317-28
pubmed: 15093539
ESMO Open. 2022 Aug;7(4):100554
pubmed: 35963179
Clin Breast Cancer. 2016 Oct;16(5):344-348
pubmed: 27405796
J Clin Oncol. 2020 Aug 10;38(23):2610-2619
pubmed: 32468955
Ann Oncol. 2021 Oct;32(10):1245-1255
pubmed: 34224826
Nat Med. 2022 Sep;28(9):1840-1847
pubmed: 35941372
Lancet Oncol. 2013 May;14(6):461-71
pubmed: 23602601
J Clin Oncol. 2005 Nov 1;23(31):7820-6
pubmed: 16258084
J Clin Oncol. 2019 May 1;37(13):1081-1089
pubmed: 30860945
Clin Cancer Res. 2022 Feb 15;28(4):618-628
pubmed: 34844975
Ann Oncol. 2006 Jun;17(6):935-44
pubmed: 16603601
Breast Cancer Res. 2016 Dec 13;18(1):126
pubmed: 27955684
JAMA Oncol. 2015 Nov;1(8):1051-9
pubmed: 26270597
Clin Cancer Res. 2019 Mar 15;25(6):1970-1979
pubmed: 30559169
Ann Oncol. 2014 Jun;25(6):1116-21
pubmed: 24685829
Neuro Oncol. 2023 Jan 5;25(1):157-166
pubmed: 35639825
JAMA Oncol. 2021 Apr 01;7(4):573-584
pubmed: 33480963
Ann Oncol. 2008 Jul;19(7):1242-1248
pubmed: 18334512
N Engl J Med. 2006 Dec 28;355(26):2733-43
pubmed: 17192538
Ann Oncol. 2017 Dec 1;28(12):3098-3099
pubmed: 28950320
Lancet Oncol. 2017 Jun;18(6):732-742
pubmed: 28526536
Eur J Cancer. 2017 Oct;84:141-148
pubmed: 28810186
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Cancer. 2014 Mar 1;120(5):642-51
pubmed: 24222194
Clin Breast Cancer. 2022 Jun;22(4):289-299
pubmed: 35246390
Ann Oncol. 2013 Oct;24(10):2630-2635
pubmed: 23868905
Breast Cancer Res Treat. 2020 Jan;179(1):161-171
pubmed: 31605311
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
Breast Cancer Res Treat. 2012 Nov;136(1):153-60
pubmed: 22968656
Breast Cancer Res. 2014 Mar 05;16(2):209
pubmed: 24887180
Cancer Treat Rev. 2012 Oct;38(6):698-707
pubmed: 22178455
Lancet Oncol. 2022 Mar;23(3):353-361
pubmed: 35085506
Cancer Res. 2017 Oct 1;77(19):5374-5383
pubmed: 28819024
J Clin Oncol. 2009 Nov 20;27(33):5538-46
pubmed: 19786658
Breast Cancer Res. 2011;13(6):R123
pubmed: 22129105
JCO Precis Oncol. 2022 Mar;6:e2100370
pubmed: 35357905
J Clin Oncol. 1999 Sep;17(9):2639-48
pubmed: 10561337
MAbs. 2016 Oct;8(7):1361-1370
pubmed: 27380003
J Clin Oncol. 2020 Sep 20;38(27):3138-3149
pubmed: 32678716